Verrica Pharmaceuticals Inc. develops and commercializes dermatological treatments in the United States. The company is advancing its lead product VP-102, a proprietary topical therapy, in various common skin indications, including Molluscum contagiosum and Verruca Vulgaris. It is also developing 2 Phase 3 trials in molluscum contagiosum under NCT03377803 and NCT03377790. The company is headquartered in West Chester, Pennsylvania.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone484-453-3300
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees11
OptionableNot Optionable
Verrica Pharmaceuticals (NASDAQ:VRCA) Frequently Asked Questions
What is Verrica Pharmaceuticals' stock symbol?
Verrica Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRCA."
How were Verrica Pharmaceuticals' earnings last quarter?
Verrica Pharmaceuticals Inc (NASDAQ:VRCA) released its quarterly earnings data on Wednesday, November, 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.25) by $0.03. View Verrica Pharmaceuticals' Earnings History.
When is Verrica Pharmaceuticals' next earnings date?
What price target have analysts set for VRCA?
3 Wall Street analysts have issued 1-year price objectives for Verrica Pharmaceuticals' shares. Their predictions range from $24.00 to $35.00. On average, they expect Verrica Pharmaceuticals' stock price to reach $28.3333 in the next year. This suggests a possible upside of 122.9% from the stock's current price. View Analyst Price Targets for Verrica Pharmaceuticals.
What is the consensus analysts' recommendation for Verrica Pharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Verrica Pharmaceuticals.
Has Verrica Pharmaceuticals been receiving favorable news coverage?
Media coverage about VRCA stock has been trending positive on Tuesday, according to InfoTrie. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Verrica Pharmaceuticals earned a news impact score of 2.1 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are some of Verrica Pharmaceuticals' key competitors?
Some companies that are related to Verrica Pharmaceuticals include Cambrex (CBM), Spectrum Pharmaceuticals (SPPI), Phibro Animal Health (PAHC), Esperion Therapeutics (ESPR), Amphastar Pharmaceuticals (AMPH), Wave Life Sciences (WVE), Vanda Pharmaceuticals (VNDA), Puma Biotechnology (PBYI), Deciphera Pharmaceuticals (DCPH), Rhythm Pharmaceuticals (RYTM), Epizyme (EPZM), Alder Biopharmaceuticals (ALDR), Tricida (TCDA), Kiniksa Pharmaceuticals (KNSA) and MacroGenics (MGNX).
Who are Verrica Pharmaceuticals' key executives?
Verrica Pharmaceuticals' management team includes the folowing people:
- Mr. Ted White, Pres, CEO & Director (Age 54)
- Mr. Chris Degnan, Chief Financial Officer (Age 38)
- Ms. Linda S. Palczuk, Chief Operating Officer (Age 57)
- Mr. Joe Bonaccorso, Chief Commercial Officer (Age 55)
- Dr. Patrick Burnett M.D., Ph.D., Chief Medical Officer (Age 47)
When did Verrica Pharmaceuticals IPO?
(VRCA) raised $75 million in an IPO on Friday, June 15th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen served as the underwriters for the IPO.
Who are Verrica Pharmaceuticals' major shareholders?
Verrica Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Kornitzer Capital Management Inc. KS (1.27%), BlackRock Inc. (1.04%), Diag Capital Management LP (0.45%), Sphera Funds Management LTD. (0.38%), Northern Trust Corp (0.26%) and Pura Vida Investments LLC (0.25%). Company insiders that own Verrica Pharmaceuticals stock include Chris Degnan, Joe Bonaccorso, Life Sciences Maste Perceptive, Linda Palczuk, Matt Davidson, Paul B Manning, Sean Stalfort and Ted White. View Institutional Ownership Trends for Verrica Pharmaceuticals.
Which institutional investors are selling Verrica Pharmaceuticals stock?
Which institutional investors are buying Verrica Pharmaceuticals stock?
VRCA stock was purchased by a variety of institutional investors in the last quarter, including Diag Capital Management LP, Kornitzer Capital Management Inc. KS, Pura Vida Investments LLC, BlackRock Inc., Beck Mack & Oliver LLC, Geode Capital Management LLC, Northern Trust Corp and Bank of New York Mellon Corp. Company insiders that have bought Verrica Pharmaceuticals stock in the last two years include Chris Degnan, Joe Bonaccorso, Life Sciences Maste Perceptive, Linda Palczuk, Paul B Manning, Sean Stalfort and Ted White. View Insider Buying and Selling for Verrica Pharmaceuticals.
How do I buy shares of Verrica Pharmaceuticals?
Shares of VRCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Verrica Pharmaceuticals' stock price today?
One share of VRCA stock can currently be purchased for approximately $12.71.
How big of a company is Verrica Pharmaceuticals?
Verrica Pharmaceuticals has a market capitalization of $326.60 million. Verrica Pharmaceuticals employs 11 workers across the globe.
What is Verrica Pharmaceuticals' official website?
How can I contact Verrica Pharmaceuticals?
Verrica Pharmaceuticals' mailing address is 10 North High Street Suite 200, West Chester PA, 19380. The company can be reached via phone at 484-453-3300 or via email at [email protected]
MarketBeat Community Rating for Verrica Pharmaceuticals (NASDAQ VRCA)
MarketBeat's community ratings are surveys of what our community members think about Verrica Pharmaceuticals and other stocks. Vote "Outperform" if you believe VRCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
